An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Trial Profile

An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs VCL CB01 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 31 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top